The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, Myeloma30 August 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, Myeloma28 July 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, Myeloma19 October 2021
Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidence11 October 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
